Anzeige
Mehr »
Login
Mittwoch, 19.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
Drei Bohrgeräte, 23 Kilometer und die Vision, eine der 10 größten Goldminen Kanadas zu werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JH2F | ISIN: US5011471027 | Ticker-Symbol: 4KB
Tradegate
18.02.25
09:31 Uhr
145,50 Euro
-4,40
-2,94 %
1-Jahres-Chart
KRYSTAL BIOTECH INC Chart 1 Jahr
5-Tage-Chart
KRYSTAL BIOTECH INC 5-Tage-Chart
RealtimeGeldBriefZeit
150,20152,1510:24
150,20152,1510:24

Aktuelle News zur KRYSTAL BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiKrystal Biotech Q4 2024 Earnings Preview1
21.01.Pacira Names Brendan Teehan Chief Commercial Officer, Krys Corbett Chief Business Officer1
20.01.Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years5
14.01.Krystal Biotech, Inc.: Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer2
KRYSTAL BIOTECH Aktie jetzt für 0€ handeln
06.01.Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today3
19.12.24KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB7079
18.12.24Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today4
18.12.24Krystal Biotech meldet vielversprechende Ergebnisse bei Lungenkrebs-Studie12
18.12.24Krystal Biotech, Inc.: Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer99Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful...
► Artikel lesen
13.12.24KRYS Stock Down on Initial Clinical Updates on KB407 & KB4086
12.12.24Expert Ratings For Krystal Biotech16
12.12.24Krystal Biotech, Inc.: Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase ...235Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and well...
► Artikel lesen
12.12.24Krystal Biotech, Inc. - 8-K, Current Report1
09.12.24Krystal Biotech erwartet EMA-Stellungnahme zur DEB-Behandlung im 1. Quartal 20257
09.12.24Krystal Biotech expects EMA opinion on DEB treatment in 1Q 20251
09.12.24Krystal Biotech, Inc.: Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa104CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company")...
► Artikel lesen
05.11.24Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $206.00 at Citigroup11
04.11.24Krystal Biotech GAAP EPS of $0.91 beats by $0.01, revenue of $83.84M beats by $0.73M12
04.11.24Krystal Biotech, Inc.: Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates164Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health authority...
► Artikel lesen
04.11.24Krystal Biotech, Inc. - 10-Q, Quarterly Report2
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1